Five-Star's disbursement recovery is credible but unusually high overdue balances and a nonrecurring tax benefit make the quality of growth more…
Recovery watch; collections first
Watch: Monitor catalysts and falsifiers
Home / Research / Five-Star Business Finance
Five-Star's disbursement recovery is credible but unusually high overdue balances and a nonrecurring tax benefit make the quality of growth more important than headline PAT.
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6644875f-0e59-45cc-b109-bc5fd3e86b0b.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6644875f-0e59-45cc-b109-bc5fd3e86b0b.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6644875f-0e59-45cc-b109-bc5fd3e86b0b.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6644875f-0e59-45cc-b109-bc5fd3e86b0b.pdf
Recovery watch; collections first
Watch: Monitor catalysts and falsifiers
Issuer-reported figures and explicitly identified derived comparisons; see chapter analysis.
Watch: Compare next quarter using identical definitions.
Issuer-reported figures and explicitly identified derived comparisons; see chapter analysis.
Watch: Compare next quarter using identical definitions.
Issuer-reported figures and explicitly identified derived comparisons; see chapter analysis.
Watch: Compare next quarter using identical definitions.
Research date: 16 November 2026 | Price reference: ₹442.65 (13 November 2026)
Stance: Recovery watch; collections first. Core thesis: Five-Star's disbursement recovery is credible but unusually high overdue balances and a nonrecurring tax benefit make the quality of growth more important than headline PAT.
Key takeaways
The company is a specialist small-business secured lender: a borrower may offer property security while income remains vulnerable to local business conditions. Security limits eventual loss but cannot ensure punctual repayment.
The quarter's PAT ₹299.3 crore includes about ₹19 crore of earlier-year tax benefit. Normalized PAT approximately ₹280.3 crore. Reported PAT growth +10% QoQ becomes roughly +3% normalized, as management explicitly explained.
At ₹442.65 on 13 November the investment case must be evaluated using normalized earnings, not the tax-assisted quarter. The differentiator is the combination of high asset yields, local field collection capability and substantial equity; the countercase is persistently high arrears and declining incremental returns as growth resumes.
[1,2]
| Indicator | Q2 FY27 |
|---|---|
| AUM | ₹14,639.6 cr |
| Disbursements | ₹2,077.8 cr |
| PAT reported | ₹299.3 cr |
| PAT ex ₹19 cr tax benefit | ~₹280.3 cr |
| NIM / average AUM | 19.87% |
| ROAA / ROE | 8.39% / 15.25% |
| Net worth | ~₹7,903 cr |
Key takeaways
The implied normalized growth is 3.3%, consistent with management's rounded statement. Reported ROAA rose 28 bps QoQ, but the tax benefit improves that ratio too; a normalized comparison should recalculate using average assets and adjusted tax.
Yield was 22.26%, cost of funds 8.78% and NIM 19.87% on average AUM. NIM is not yield less debt cost: equity funding means not all loan assets have interest-bearing debt funding, and the definitions differ. Management reported cost-to-income including credit costs above 47%. This ratio is not directly comparable with operating cost/income excluding impairment at other NBFCs. [1,2]
Key takeaways
Management has focused on increasing ticket size as well as adding customers. This can improve field economics because the same relationship officer can generate more principal, but increased ticket size raises exposure per borrower. Monitor cash flow, leverage and collateral value rather than assuming all secured expansion carries the same risk.
The 875-branch network includes 19 new branches in Q2 and 75 over the year. Core geographies Tamil Nadu, Andhra Pradesh and Telangana represent over 80% per management Q&A. Local knowledge is a competitive advantage, but clustered rainfall, demand, regulation or collection disruption can create correlated losses.
Deepening an established geography can produce better borrower knowledge than premature diversification; however, concentration reduces resilience to regional shocks. At 875 branches, simple AUM per branch is ₹16.7 crore, with no adjustment for age or geography.
Disbursement per branch approximately ₹2.37 crore per quarter. These are aggregate throughput measures, not mature-branch contribution. [1,2]
Key takeaways
This matters because a decline in a percentage caused merely by AUM expansion would be less convincing. Gross Stage 3 remains 84 bps above last year. Improving current collections are encouraging but do not eliminate a material stock of overdue loans.
At the current AUM, 11.5% 30+ DPD implies roughly ₹1,684 crore on a consistent AUM denominator; this is an illustrative estimate, not reported 30+ exposure. A 50-bp annualized credit-cost shock is about ₹73 crore pretax; a 100-bp shock ₹146 crore.
Compared with normalized annualized PAT ₹1,121 crore these are significant even before accounting for the tax shield. The most informative recovery evidence is absolute Stage 2 reduction, roll-forward from 30+ to Stage 3, cures net of write-offs and collections on old cohorts.
Management expects flat slippage and credit cost for the remaining year; stress cases should challenge this rather than assume a smooth cure. [1,2]
Key takeaways
Management expects the tightening rate cycle to increase funding cost and has increased yield on incremental loans effective October. Passing higher rates to fresh borrowers can protect margin; it may also weaken affordability or change borrower selection. The effect on the existing book depends on repricing terms and duration.
Net worth near ₹7,903 crore against AUM ₹14,640 crore suggests a capital-heavy franchise with AUM/equity roughly 1.85x. This is not statutory debt/equity, but it helps explain why 8.39% asset returns translate to only 15.25% equity returns.
The upside is controlled capital deployment; the downside is that growing faster simply increases exposure to a stressed borrower base. Capital strength should be used to maintain underwriting rather than maximize leverage.
A full maturity profile, debt covenants, encumbered cash and interest reset schedule remain necessary for a complete ALM assessment. [2]
Key takeaways
The scenario values at 9x, 13x and 16x respectively are illustrative equity values of about ₹8,577 crore, ₹16,762 crore and ₹22,424 crore, not per-share targets. Multiples are analyst assumptions, not peer observed. The 13 November price ₹442.65 must be compared with audited fully diluted shares before interpreting upside or downside.
The central valuation driver is normalized ROE and loss intensity, not the headline yield. An 8% asset return is valuable only if the capital base can compound at acceptable credit risk. A reduced risk premium could follow a multi-quarter decline in absolute overdue balances.
Conversely, a second cycle of elevated arrears would warrant a lower multiple even if reported PAT continues rising. The nonrecurring tax benefit is explicitly excluded from the run-rate; no blanket assumption that future tax credits recur.
[1,2]
| Case | Annual PAT ₹ crore | Assumed multiple | Equity value ₹ crore |
|---|---|---|---|
| Bear | 953 | 9x | 8577 |
| Base | 1289 | 13x | 16757 |
| Bull | 1402 | 16x | 22432 |
Normalize the tax benefit before pricing. Q2 reported PAT ₹299.3 crore includes ~₹19 crore prior-year tax benefit, giving normalized ~₹280.3 crore. The adjustment is 6.3% of reported PAT; annualizing reported profit gives ₹1,197.2 crore versus ₹1,121.2 crore normalized, a ₹76 crore difference.
Q1 inferred ₹271.4 crore. Reported sequential growth 10.3%, normalized 3.3%. At unchanged valuation multiple, using the higher run-rate would mechanically inflate equity value ~6.8% relative to normalized earnings.
The investment case should require recurring profit acceleration, not an accounting tax effect. H1 reported PAT ₹570.7 crore becomes ~₹551.7 crore after this one adjustment; it is not an audited adjusted P&L because other items remain to reconcile.
| Earnings lens | ₹ crore |
|---|---|
| Q1 PAT (inferred) | 271.4 |
| Q2 reported | 299.3 |
| Q2 tax-adjusted | 280.3 |
| Annualized tax-adjusted Q2 | 1,121.2 |
Recovery in the old book matters more than the new flow. 30+ DPD 12.38%→11.50%, gross Stage 3 3.48%, Stage 2 ₹1,173 crore versus ₹1,225 crore prior year. With Q2 AUM +7% QoQ, inferred June AUM ~₹13,682 crore, approximate 30+ stock on the stated AUM proxy 12.38%×13,682≈₹1,694 crore vs September 11.5%×14,640≈₹1,684 crore.
This suggests only ~₹10 crore reduction in the illustrative absolute 30+ stock despite a 0.88-point ratio improvement; exact DPD denominator and rounded AUM growth must be verified. The actual Stage 2 amount declined ₹52 crore YoY, more direct evidence.
Require actual monthly stage roll-forward: beginning overdue plus new slippage minus cash cures, write-offs and sales, ending overdue. Ratio improvement from denominator growth is weaker than cash cures.
Current-bucket collection 84.78% and X-bucket 99.4% measure different populations; neither substitutes for delinquent recoveries.
Borrower-level loan growth. AUM +14% YoY versus active loans +5% implies average outstanding per active loan +8.6%, assuming consistent scope. Current proxy ₹2.87 lakh, prior ~₹2.64 lakh. Bigger tickets can improve officer productivity but increase loss severity and affordability risk.
Separate loans to new borrowers, repeat top-ups, scheduled repayment and refinance. A small-business borrower may have property collateral but irregular daily/seasonal income. Underwrite cash flows, household/business obligations, title and LTV; compare repayment history by ticket and geography.
Over 80% exposure in Tamil Nadu/AP/Telangana per management increases correlated local risk; a regional shock could affect multiple borrowers even if individual loan size is small. Do not interpret geographic familiarity as immunity.
Review recovery by field officer/branch, local income and actual collateral realization after legal cost and delay.
Origination flow and vintage. Q2 gross disbursement ₹2,077.8 crore versus Q1 ₹1,496.4 (H1 less Q2), +38.9%. Inferred net addition ₹958 crore on rounded +7% AUM QoQ, leaving ~₹1,120 crore gross-to-net residual.
This is not reported repayment; includes amortization and other changes. The higher flow may improve future interest income, but a young book has not experienced full stress. Compare funded vintage loss at identical months-on-book, especially after the recent origination ramp, and track active customer count rather than ticket alone.
Current 875 branches imply Q2 disbursement ~₹2.37 crore/branch on closing denominator; a new branch is not comparable to mature. Measure net field contribution after collections, credit and capital, not gross origination.
Normalize credit and capital simultaneously. At net worth ₹7,903 crore and tax-adjusted annual PAT ₹1,121 crore, closing-book return proxy ~14.2%, below issuer 15.25% reported average ROE (tax benefit/denominator differ). At 14% illustrative equity hurdle ₹1,106 crore, residual economic profit only ~₹15 crore; at 13% hurdle ~₹94 crore.
To reach 18% return on static book needs ~₹1,423 crore annual PAT, ~27% above current normalized run-rate before further equity growth. A high reported ROAA does not automatically create a high per-share return when equity is underdeployed.
A 50bp gross annual loss shock ~₹73 crore pretax (~₹55 crore after assumed 25% tax) would reduce normalized PAT to ~₹1,066 crore, below the illustrative 14% charge. If normalized profit grows 15% while equity grows 10%, closing return rises only to ~14.8%.
These are static sensitivity calculations, not actual average equity forecast.
Valuation and decision. A long-term justified P/B with sustainable ROE 11%/16%/19%, cost of equity 16%/14%/13%, long-run growth 4%/6%/7% gives ~0.58x/1.25x/2.0x terminal economics. The existing earnings multiple scenarios should be read as valuation sensitivities, not target prices; exact current diluted shares/book still needed.
At ₹442.65, the most valuable catalyst is absolute overdue reduction and normalized ROE expansion with origination recovery. Track stage 2 below ₹1,173 crore, 30+ stock (not just ratio), new-vintage cash cures, credit cost near or below 1.8% and reported PAT excluding tax benefits.
If disbursements rise while absolute overdue and credit losses persist, reduce growth conviction. If cash cures accelerate and operating contribution rises, higher capital deployment can create durable value.
The thesis is a recovery, not an assumption that secured borrowers always repay.
A more stringent test of recovery is to set an absolute overdue objective rather than relying on a falling ratio. On the current managed AUM proxy of ₹14,639.6 crore, the 11.50% 30+ DPD rate implies approximately ₹1,684 crore of overdue exposure.
At unchanged AUM, a 10% ratio would imply ₹1,464 crore, requiring about ₹220 crore of net reduction in the proxy. If AUM instead expanded by 10%, the same 10% ratio would allow an overdue balance of approximately ₹1,610 crore, just ₹74 crore below the starting proxy.
Both calculations use a consistent closing managed-AUM denominator rather than the actual reported DPD denominator, which needs verification. The contrast demonstrates why investors should demand cash cures net of new arrears and write-offs as well as percentages.
A ratio improvement generated principally by expanding healthy origination may be less persuasive than declining absolute stressed loans. Track actual monthly overdue stocks and the transfer of loans between delinquency stages.
The regional concentration also merits its own scenario. Management identifies Tamil Nadu, Andhra Pradesh and Telangana as more than 80% of the portfolio. Using 80% only as a lower-bound mix illustration on the disclosed AUM gives about ₹11,712 crore of exposure.
An extra annual loss of 50 or 100 basis points on that proxy would be approximately ₹58.6 crore or ₹117.1 crore before tax. These are hypothetical correlated regional stresses, not forecasts and not additional to an aggregate credit-cost sensitivity that already covers the same loans.
With an assumed 25% marginal tax rate the latter charge would lower annual PAT by roughly ₹88 crore if fully recognised, about 7.8% of the normalized ₹1,121.2 crore run-rate. The local underwriting advantage can reduce individual borrower risk, but it cannot eliminate common shocks to business turnover, property liquidity or collections.
The decision test is the actual geographical roll-rate and recovery history during prior stressed periods, with disbursement growth constrained by observed loss.
A separate capital and funding question follows from the shift in bank borrowing share from 67% to 69%. The reported ₹825 crore new debt at 8.43%, compared with portfolio funding cost of 8.78%, represents a 35 basis-point difference.
On the newly raised amount alone, a hypothetical annual gross interest saving versus the portfolio rate is about ₹2.89 crore before issue costs and tenor effects. It would be misleading to apply the entire 35 basis points immediately to all liabilities or managed assets.
If the new borrowing replaces higher-priced maturities, the actual savings depend on the replaced principal, coupon and date; if it funds growth, additional risk-adjusted asset contribution determines profitability. The bank mix can support funding access but increases the importance of lender limits and renewal terms.
The announced yield rise on new loans likewise needs a vintage-specific comparison, with affordability and prepayment effects included.
Five-Star's large equity base can absorb temporary losses, but the objective should be a durable rise in normalized return rather than accelerated leverage alone. The current closing AUM/equity proxy is about 1.85x.
If AUM rose 15% with equity unchanged it would reach about 2.13x; if equity simultaneously rose 10%, it would reach only about 1.94x. Neither ratio is statutory leverage or a regulatory capital forecast.
It illustrates that retained earnings and capital accumulation can dilute the effect of asset growth on equity returns. Reconcile actual borrowings, equity changes and risk-weighted assets alongside recurring profit.
The most credible route to higher ROE is increasing the cash return on seasoned loans and field productivity while maintaining prudent liquidity, not using the balance sheet's available capacity to accelerate lending into weak vintages.
Key takeaways
A rising gross Stage 3 despite faster disbursements would undermine it; so would increasing write-offs presented as cures. Monitor funding mix and yield increases effective October. The normalized earnings growth of ~3% sequentially provides a more conservative starting point than the reported 10%. This edition relies on original issuer documents, but requires statutory share reconciliation, geography-level loss vintages, collateral realization and independent ALM before a formal valuation or full investment committee approval. [1,2]
[1] Q2 FY27 investor presentation, 2026-10-26, original filing.
[2] Q2 FY27 earnings call, 2026-10-26, original filing.
Prices: Sage PRO canonical close, 13 November 2026. Analyst calculations and stress assumptions are explicitly labeled; no independent full-QA approval. Monetary figures are ₹ crore unless otherwise noted. Open issues: Audited diluted shares, collateral recovery vintage cohorts and ALM; no per-share target.
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6644875f-0e59-45cc-b109-bc5fd3e86b0b.pdf
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6644875f-0e59-45cc-b109-bc5fd3e86b0b.pdf
Analyst scenario calculations
Original Q2 source ledger and analyst calculations
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.